Serial Vasopressin and Copeptin Levels in Children With Sepsis and Septic Shock

NCT ID: NCT00698048

Last Updated: 2015-09-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

136 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-08-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients with severe infection can develop very low blood pressure. There are many mechanisms leading to this, and one of them appears to involve a hormone called vasopressin. In children as compared to adults, the mechanism and response to low blood pressure are different for reasons that are not clear. One possibility is the difference in the production and/or response to vasopressin. Vasopressin has become part of the treatment of children with low blood pressure in the setting of severe infection, when other treatment has failed, but its use is on the basis of animal and adult studies. The exact timing and dose is uncertain.

In this research study, the patients will receive standard treatment for sepsis and septic shock, and the investigators will measure the blood levels of vasopressin and a related compound called copeptin (both are required to understand the mechanism of control involved). Blood will need to be taken from patients without any sepsis so as to be able to compare the values in health and in sickness. The patient groups the investigators have chosen for this are those children who will have blood taken anyway as part of their routine care. The aim of this study is to develop an understanding of the body's hormonal response (with respect to vasopressin) to severe infection in children. The long-term aim is to improve the care of critically ill children with severe infection by using the most appropriate dose of vasopressin at the most appropriate time.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Controls

No interventions assigned to this group

2

Sepsis

No interventions assigned to this group

3

Septic Shock

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Control Group:

* Neonates admitted for neonatal jaundice requiring phototherapy
* Previously well patients admitted for elective gastrointestinal endoscopy, patients admitted for non-specific abdominal pain and
* Pre-operative patients for circumcision, inguinal hernias and chronic orthopaedic conditions

Study Group:

* The investigators will also enroll children with sepsis and septic shock
* Sepsis will be defined as proposed by the International pediatric sepsis consensus conference.
* Children will be recruited into the septic shock group if they have sepsis and features of cardiovascular organ dysfunction as defined by the same consensus conference.

Exclusion Criteria

* Neonates weighing less than 2.5 kg
* Neonates less than 36 weeks gestation
* Children more than 16 years of age
* Patients with a history of congenital heart disease
* Patients with chronic renal impairment
* Patients with chronic liver impairment
* Patients on active chemotherapy
* Patients on chronic mineralocorticoids or glucocorticoids therapy
* Patients on long-term diuretic therapy
* Patients with central nervous system tumours
* Patients with developmental delay
Minimum Eligible Age

1 Day

Maximum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Medical Research Council (NMRC), Singapore

OTHER_GOV

Sponsor Role collaborator

Jan Hau Lee

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jan Hau Lee

Dr Lee Jan Hau

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jan Hau Lee, MRCPCH(UK)

Role: PRINCIPAL_INVESTIGATOR

KK Women's and Children's Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

KK Women's and Children's Hospital

Singapore, , Singapore

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Singapore

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIG07nov002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nesiritide Use Following Cardiac Surgery in Infants
NCT00281671 TERMINATED PHASE1/PHASE2
Use of Vasopressin Following the Fontan Operation
NCT02975999 COMPLETED PHASE2/PHASE3